Higher Overseas Sales Ratio
First written in FY2016. 1 of 37 entries say "Cited as achieved", first in 2026-05-14. Latest entry: 2026-08-07.
The whole theme swung hardest in 2017: 1 of 8 companies on the "Worse" side.
6 other companies' latest entry also says "Other".
- 2026-08-07OtherEarnings
「Overseas revenue was ¥113,283 million, up 19.6% year on year, while its share of total revenue was 86.7%, down 2.9 percentage points year on year.」
Overseas revenue increased, while its share of total revenue declined from the same period of the previous year. - FY2026Updated full-year overseas sales ratioAnnual report
「Overseas revenue was ¥441,403 million, up 0.1% year on year, and accounted for 88.3% of total revenue, an increase of 1.6 percentage points year on year.」
The full-year overseas sales ratio increased from 86.7% in the previous fiscal year to 88.3%. Overseas sales increased 0.1% from the previous fiscal year. - 2026-05-14Cited as achievedRevisions to earnings forecasts
「Overseas revenue was ¥441,403 million, up 0.1% year on year, and accounted for 88.3% of total revenue, an increase of 1.6 percentage points year on year.」
The full-year overseas revenue mix was updated. - FY2026-H1Updated the overseas sales ratio for the first half.Annual report
「In overseas sales, sales of equipment, reagents and maintenance services in the hematology field declined, and the yen remained strong against other currencies. As a result, overseas sales totaled ¥207,092 million, down 2.4% year on year, accounting for 89.1% of sales, up 1.6 percentage points year on year.」
Overseas sales for the interim period of the fiscal year ending September 2025 totaled ¥207,092 million, accounting for 89.1% of sales. Overseas sales declined 2.4% year on year, while the share increased from 87.5%. - FY2025-H1Updated the overseas sales ratio for the first half.Annual report
「Overseas sales totaled ¥212,156 million, up 14.7% year on year, accounting for 87.5% of sales, up 0.5 percentage points year on year.」
Overseas sales for the interim period of the fiscal year ending March 2025 totaled ¥212,156 million, accounting for 87.5% of sales, with both sales and the share increasing from the same period of the previous year. - FY2024Updated full-year overseas sales ratioAnnual report
「Overseas sales totaled ¥399,325 million, up 13.9% from the previous fiscal year, accounting for 86.5% of sales, up 1.1 percentage points from the previous fiscal year.」
Overseas sales for the full fiscal year totaled ¥399,325 million, accounting for 86.5% of sales, with both sales and the share increasing from the previous fiscal year. - FY2024-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「In overseas sales, sales of equipment, reagents and maintenance services in the hematology field increased. In addition, the yen remained weak against other currencies. As a result, overseas sales totaled ¥283,210 million, up 11.1% year on year, accounting for 86.7% of sales, up 1.3 percentage points year on year.」
Overseas sales for the cumulative third quarter totaled ¥283,210 million, accounting for 86.7% of sales, with both sales and the share increasing from the same period of the previous year. - FY2024-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「Overseas sales totaled ¥185,030 million, up 12.0% year on year, accounting for 87.0% of sales, up 1.9 percentage points year on year.」
Overseas sales for the cumulative second quarter totaled ¥185,030 million, accounting for 87.0% of sales, with both sales and the share increasing from the same period of the previous year. - FY2024-Q1Updated first-quarter overseas sales ratioAnnual report
「In overseas sales, sales of reagents and maintenance services in the hematology field and reagents in the urinalysis field increased. In addition, the yen remained weak against other currencies. As a result, overseas sales totaled ¥82,315 million, up 12.7% year on year, accounting for 86.3% of sales, up 1.4 percentage points year on year.」
Overseas sales for the first quarter totaled ¥82,315 million, accounting for 86.3% of sales. Sales increased 12.7% year on year, while the share increased by 1.4 percentage points. - FY2023Updated full-year overseas sales ratioAnnual report
「Overseas sales totaled ¥350,669 million, up 13.8% from the previous fiscal year, accounting for 85.4% of sales, up 0.7 percentage points from the previous fiscal year.」
Overseas sales for the full fiscal year totaled ¥350,669 million, accounting for 85.4% of sales, with both sales and the share increasing from the previous fiscal year. - FY2023-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥254,978 million, up 16.1% year on year, accounting for 85.4% of sales, up 0.5 percentage points year on year.」
Overseas sales for the cumulative third quarter totaled ¥254,978 million, accounting for 85.4% of sales. Sales increased 16.1% year on year, while the share increased by 0.5 percentage points. - FY2023-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥165,229 million, up 15.4% year on year, accounting for 85.1% of sales, up 0.1 percentage points year on year.」
Overseas sales for the cumulative second quarter totaled ¥165,229 million, accounting for 85.1% of sales. Overseas sales increased 15.4% year on year, while the share increased by 0.1 percentage points. - FY2023-Q1Updated first-quarter overseas sales ratioAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥73,065 million, up 8.8% year on year, accounting for 84.9% of sales, up 0.3 percentage points year on year.」
Overseas sales for the first quarter totaled ¥73,065 million, accounting for 84.9% of sales. Sales increased 8.8% year on year, while the share increased by 0.3 percentage points. - FY2022Updated full-year overseas sales ratioAnnual report
「Overseas sales totaled ¥308,161 million, up 20.2% from the previous fiscal year, accounting for 84.7% of sales, up 0.7 percentage points from the previous fiscal year.」
Overseas sales for the fiscal year ending March 2022 totaled ¥308,161 million, and the overseas sales ratio was 84.7%, with both increasing from the previous fiscal year. - FY2022-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology and urinalysis fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥219,618 million, up 23.0% year on year, accounting for 84.9% of sales, up 0.6 percentage points year on year.」
Overseas sales for the cumulative third quarter totaled ¥219,618 million, accounting for 84.9% of sales. Sales increased 23.0% year on year, while the share increased by 0.6 percentage points. - FY2022-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「Overseas sales totaled ¥143,196 million, up 29.2% year on year, accounting for 85.0% of sales, up 1.1 percentage points year on year.」
Overseas sales for the cumulative second quarter totaled ¥143,196 million, accounting for 85.0% of sales, up 1.1 percentage points from 83.9% in the same period of the previous year. - FY2022-Q1Updated first-quarter overseas sales ratioAnnual report
「As a result, the Group's overseas sales totaled ¥67,136 million, up 31.3% year on year, accounting for 84.6% of sales, up 0.1 percentage points year on year.」
Overseas sales for the first quarter totaled ¥67,136 million, accounting for 84.6% of sales. Overseas sales increased 31.3% year on year, while the share increased by 0.1 percentage points. - FY2021Updated full-year overseas sales ratioAnnual report
「Overseas sales totaled ¥256,316 million, up 0.4% from the previous fiscal year, accounting for 84.0% of sales, down 0.5 percentage points from the previous fiscal year.」
Overseas sales increased to ¥256,316 million, while the overseas sales ratio stood at 84.0%, down 0.5 percentage points from the previous fiscal year. - FY2021-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「In overseas sales, equipment sales increased in the urinalysis, blood coagulation testing and immunochemistry testing fields, but reagent sales declined mainly in the hematology, urinalysis and immunochemistry testing fields, primarily due to the impact of the spread of COVID-19. As a result, the Group's overseas sales totaled ¥178,553 million, down 3.0% year on year, accounting for 84.3% of sales, down 0.1 percentage points year on year.」
Overseas sales for the cumulative third quarter totaled ¥178,553 million, accounting for 84.3% of sales. Overseas sales declined 3.0% year on year, while the share declined by 0.1 percentage points. - FY2021-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「As a result, the Group's overseas sales totaled ¥110,807 million, down 7.9% year on year, accounting for 83.9% of sales, down 0.2 percentage points year on year.」
Overseas sales for the cumulative second quarter totaled ¥110,807 million, accounting for 83.9% of sales. Overseas sales declined 7.9% year on year, while the share declined by 0.2 percentage points. - FY2021-Q1Updated first-quarter overseas sales ratioAnnual report
「As a result, the Group's overseas sales totaled ¥51,130 million, down 12.4% year on year, accounting for 84.5% of sales, down 0.7 percentage points year on year.」
Overseas sales for the first quarter totaled ¥51,130 million, accounting for 84.5% of sales. Overseas sales declined 12.4% year on year, while the share declined by 0.7 percentage points. - FY2020Updated full-year overseas sales ratioAnnual report
「Overseas sales totaled ¥255,255 million, up 2.3% from the previous fiscal year, accounting for 84.5% of sales, down 0.5 percentage points from the previous fiscal year.」
Overseas sales increased 2.3% from the previous fiscal year to ¥255,255 million, while the overseas sales ratio declined 0.5 percentage points from the previous fiscal year to 84.5%. - FY2020-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「In overseas sales, although reagent sales declined mainly in the blood coagulation testing field, reagent sales grew mainly in the hematology, urinalysis and immunochemistry testing fields. As a result, the Group's overseas sales totaled ¥184,167 million, up 4.3% year on year, accounting for 84.4% of sales, down 0.3 percentage points year on year.」
Overseas sales for the cumulative third quarter totaled ¥184,167 million, accounting for 84.4% of sales. Overseas sales increased 4.3% year on year, while the share declined by 0.3 percentage points. - FY2020-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「In overseas sales, reagent sales declined mainly in the blood coagulation testing field, but increased in the hematology, urinalysis and immunoassay fields. As a result, the Group’s overseas sales were ¥120,298 million, up 4.4% year on year, and accounted for 84.1% of sales, down 0.5 percentage points year on year.」
Overseas sales for the cumulative second quarter totaled ¥120,298 million, accounting for 84.1% of sales. Overseas sales increased 4.4% year on year, while the overseas sales ratio declined by 0.5 percentage points. - FY2020-Q1Updated first-quarter overseas sales ratioAnnual report
「As a result, the Group’s overseas sales were ¥58,399 million, up 3.5% year on year, and accounted for 85.2% of sales, down 0.3 percentage points year on year.」
First-quarter overseas sales were ¥58,399 million, accounting for 85.2% of sales. Overseas sales increased year on year, while the overseas sales ratio declined 0.3 percentage points. - FY2019-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「Overseas sales were ¥176,548 million, up 3.7% year on year, and accounted for 84.7% of sales, up 0.6 percentage points year on year.」
Cumulative third-quarter overseas sales were ¥176,548 million, accounting for 84.7% of sales. Overseas sales increased 3.7% year on year, while their share rose 0.6 percentage points. - FY2019-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「Overseas sales were ¥115,257 million, up 4.8% year on year, and accounted for 84.6% of sales, up 0.7 percentage points year on year.」
Cumulative second-quarter overseas sales were ¥115,257 million, accounting for 84.6% of sales. Both overseas sales and the overseas sales ratio increased from the same period of the previous fiscal year. - FY2019-Q1Updated first-quarter overseas sales ratioAnnual report
「As a result, the Group’s overseas sales were ¥56,398 million, up 7.8% year on year, and accounted for 85.5% of sales, up 0.7 percentage points year on year.」
First-quarter overseas sales were ¥56,398 million, accounting for 85.5% of sales. Both overseas sales and the overseas sales ratio increased from the same period of the previous fiscal year. - FY2018Updated full-year overseas sales ratioAnnual report
「Overseas sales were ¥236,915 million, up 14.8% year on year, and accounted for 84.0% of sales, up 1.4 percentage points year on year.」
The full-year overseas sales ratio was 84.0%, up 1.4 percentage points from 82.6% in the previous fiscal year. Overseas sales also increased 14.8% year on year. - FY2018-Q3Updated cumulative third-quarter overseas sales ratioAnnual report
「As a result, the Group’s overseas sales were ¥170,300 million, up 13.6% year on year, and accounted for 84.1% of sales, up 1.2 percentage points year on year.」
Cumulative third-quarter overseas sales were ¥170,300 million, accounting for 84.1% of sales. Overseas sales increased 13.6% year on year, while their share rose 1.2 percentage points. - FY2018-Q2Updated cumulative second-quarter overseas sales ratioAnnual report
「In overseas sales, instrument sales declined mainly in the blood coagulation testing field, while reagent sales increased in the hematology and blood coagulation testing fields. As a result, overseas sales were ¥109,951 million, up 12.4% year on year, and accounted for 83.9% of sales, up 1.6 percentage points year on year.」
Cumulative second-quarter overseas sales were ¥109,951 million, accounting for 83.9% of sales. Overseas sales increased 12.4% year on year, while their share rose 1.6 percentage points. - FY2018-Q1Overseas sales ratio rose year on yearAnnual report
「As a result, the Group’s overseas sales were ¥52,325 million, up 4.7% year on year, and accounted for 84.8% of sales, up 0.4 percentage points year on year.」
The overseas sales ratio in the first quarter was 84.8%, up 0.4 percentage points from 84.4% in the same period of the previous fiscal year. - FY2017Updated full-year overseas sales ratioAnnual report
「Domestic sales increased ¥3,621 million, or 9.1%, year on year to ¥43,467 million, while overseas sales decreased ¥6,344 million, or 3.0%, to ¥206,431 million. As a result, the overseas sales ratio declined 1.6 percentage points year on year to 82.6%.」
The full-year overseas sales ratio was 82.6%, down 1.6 percentage points from 84.2% in the previous fiscal year. - FY2017-Q3Ratio disclosed for the cumulative third quarterAnnual report
「However, mainly due to the yen’s appreciation against other currencies, the Group’s overseas sales were ¥149,923 million, down 4.7% year on year, and accounted for 82.9% of sales, down 1.8 percentage points year on year.」
The overseas sales ratio rose from 82.3% in the cumulative second quarter to 82.9%, but declined 1.8 percentage points year on year. - FY2017-Q2Ratio declined year on yearAnnual report
「However, mainly due to the yen’s appreciation against other currencies, the Group’s overseas sales were ¥97,793 million, down 4.6% year on year, and accounted for 82.3% of sales, down 1.9 percentage points year on year.」
The overseas sales ratio declined from 84.2% in the same period of the previous fiscal year to 82.3%, while overseas sales fell 4.6% year on year. - FY2017-Q1Ratio declined year on yearAnnual report
「As a result, the Group’s overseas sales were ¥49,965 million, up 0.2% year on year, and accounted for 84.4% of sales, down 2.1 percentage points year on year.」
The overseas sales ratio declined 2.1 percentage points, from 86.5% in the same period of the previous fiscal year to 84.4%. - FY2016First statedAnnual report
「Overseas sales as a percentage of consolidated net sales increased year by year, from 78.2% in the fiscal year ended March 2014 to 81.7% in the fiscal year ended March 2015 and 84.3% in the fiscal year ended March 2016.」
The disclosure quantitatively shows that the overseas sales ratio rose over the three-year period.